03:10 , Nov 3, 2018 |  BioCentury  |  Politics, Policy & Law

Backing into value with Part B

The Trump Administration’s proposed revamp of Medicare Part B would cede value determinations to other countries by importing their cost-effectiveness standards on drug pricing. It could also lead to more experiments with alternative models for...
20:43 , Nov 17, 2017 |  BC Extra  |  Politics & Policy

Multi-stakeholder group launches value assessment tool

The Innovation and Value Initiative has launched its Open-Source Value Project, which seeks to bring greater transparency to the estimation of new therapeutics' value via an interactive online platform. The tool incorporates published data from...
20:21 , Aug 18, 2017 |  BioCentury  |  Finance

Close affiliation

A fresh investment in antibody manufacturing capacity in China will enable both Seattle-based Just Biotherapeutics Inc. and its affiliate Hangzhou Just Biotherapeutics Ltd. to scale up for late stage trials and commercial launches. The U.S....
23:29 , May 11, 2017 |  BC Extra  |  Company News

Avalere, FasterCures launch patient-focused value framework

The Avalere Health LLC unit of Inovalon Holdings Inc. (Bowie, Md.) and policy and advocacy organization FasterCures launched a Patient-Perspective Value Framework (PPVF), which aims to incorporate patient preferences into assessments of the value of...
03:11 , Dec 1, 2015 |  BC Extra  |  Politics & Policy

MSKCC, ICER propose value-based pricing policies

In an Memorial Sloan Kettering Cancer Center 's Peter Bach and Institute for Clinical and Economic Review President Steven Pearson proposed a set of policies private and public payers could adopt to promote the use...
08:00 , Nov 2, 2015 |  BioCentury  |  Strategy

Three's company

The National Comprehensive Cancer Network is the third physician group to launch a tool to assess the value of cancer drugs. Unlike the others, which compare drug benefits to a reported price, NCCN is asking...
02:05 , Aug 26, 2015 |  BC Extra  |  Politics & Policy

NCCN tool will compare cancer drugs' cost-effectiveness

In October, the National Comprehensive Cancer Network plans to launch a tool to compare the cost-effectiveness of cancer treatments. The tool will incorporate metrics including cost, efficacy, safety, quality of evidence and consistency of evidence....
01:12 , Jul 25, 2015 |  BC Extra  |  Politics & Policy

Docs decry high cost of cancer drugs

More than 100 oncologists said that the high price of cancer drugs is negatively affecting the care of patients and called on patients to form a grassroots organization to advocate for more rational drug prices....
07:00 , Jul 20, 2015 |  BioCentury  |  Strategy

Indications of value

Express Scripts Holding Co. is working with companies to test not only an indication-based pricing model for drugs approved to treat more than one cancer, but also a handful of new tools that tie clinical...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Clinical News

GenomEra Clostridium difficile assay regulatory update

Abacus received CE Mark approval for its GenomEra Clostridium difficile assay to detect toxin-producing Clostridium difficile directly from stool samples. Abacus immediately launched the product in Europe. The PCR-based assay detects the toxin B gene...